Series C investment for D-BSSE-spinoff BioVersys enables Phase 2 clinical trials
BioVersys, a 2010-founded privately owned Swiss pharmaceutical company originating from the Biotechnology lab of Martin Fussenegger, extends its Series C investment round to CHF 32.6 million, which will be used to support the clinical development of BV100, a potential breakthrough hospital antibiotic targeting the most drug-resistant bacterial pathogen,Acinetobacter baumannii, which will soon be tested for the first time in a Phase 2 clinical trial.
BioVersys focusses on the research and development of therapies for life-threatening multi drug-resistant bacterial infections. The Basel-based firm represents the first European-based investment of the AMR Action Fund, a Boston-based public-private partnership that invests in biotech companies specialised on R&D on antimicrobials.
Find external pagemedia release by BioVersys (issued on 6 January 2023).
Learn about all D-BSSE spinoff companies.